Episode Details
Back to EpisodesLumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
Published 1 year, 6 months ago
Description
The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.
Learn more about your ad choices. Visit megaphone.fm/adchoices